Zimmer Biomet (NYSE:ZBH) Rating Increased to Buy at Wall Street Zen

Key Points

• Wall Street Zen upgraded Zimmer Biomet from a hold to a buy, adding to a mixed analyst outlook that still leaves the stock with a consensus rating of hold.
• Zimmer Biomet reported better-than-expected quarterly results, with EPS of $2.09 versus estimates of $1.86 and revenue of $2.09 billion, up 9.3% year over year.
• The stock has been trading below recent averages, with shares at $82.24 versus 50-day and 200-day moving averages above $91, while the company also issued FY 2026 EPS guidance of 8.40 to 8.55.

Zimmer Biomet (NYSE:ZBH - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a report issued on Saturday.

Other analysts have also issued reports about the stock. Weiss Ratings raised shares of Zimmer Biomet from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Tuesday, April 7th. Citizens Jmp dropped their price target on shares of Zimmer Biomet from $120.00 to $105.00 and set a "market outperform" rating on the stock in a research report on Wednesday, April 29th. Citigroup dropped their price target on shares of Zimmer Biomet from $98.00 to $95.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 29th. JPMorgan Chase & Co. dropped their price target on shares of Zimmer Biomet from $100.00 to $95.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 29th. Finally, Canaccord Genuity Group set a $83.00 price target on shares of Zimmer Biomet in a research report on Wednesday, April 29th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have issued a Hold rating and three have given a Sell rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $102.80.

Zimmer Biomet Stock Performance

Shares of ZBH stock opened at $82.24 on Friday. The company's fifty day simple moving average is $91.56 and its 200-day simple moving average is $92.31. The company has a quick ratio of 0.95, a current ratio of 1.73 and a debt-to-equity ratio of 0.50. The firm has a market cap of $15.91 billion, a PE ratio of 21.36, a P/E/G ratio of 1.93 and a beta of 0.48. Zimmer Biomet has a 12 month low of $79.83 and a 12 month high of $108.29.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings data on Tuesday, April 28th. The medical equipment provider reported $2.09 EPS for the quarter, topping analysts' consensus estimates of $1.86 by $0.23. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The business had revenue of $2.09 billion for the quarter, compared to analyst estimates of $2.07 billion. During the same quarter in the previous year, the firm posted $1.81 earnings per share. The firm's revenue for the quarter was up 9.3% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. Equities research analysts expect that Zimmer Biomet will post 8.47 EPS for the current fiscal year.

Insider Buying and Selling at Zimmer Biomet

In other news, SVP Lori Winkler sold 2,650 shares of the stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $94.66, for a total value of $250,849.00. Following the transaction, the senior vice president directly owned 10,224 shares of the company's stock, valued at $967,803.84. This represents a 20.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.28% of the stock is owned by insiders.

Hedge Funds Weigh In On Zimmer Biomet

Several large investors have recently modified their holdings of ZBH. DV Equities LLC bought a new position in shares of Zimmer Biomet in the fourth quarter valued at about $25,000. Key Financial Inc raised its position in shares of Zimmer Biomet by 164.6% in the third quarter. Key Financial Inc now owns 262 shares of the medical equipment provider's stock valued at $26,000 after purchasing an additional 163 shares during the period. Cullen Frost Bankers Inc. raised its position in shares of Zimmer Biomet by 66.7% in the third quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider's stock valued at $29,000 after purchasing an additional 116 shares during the period. Monetary Solutions Ltd bought a new position in shares of Zimmer Biomet in the fourth quarter valued at about $30,000. Finally, Root Financial Partners LLC bought a new position in shares of Zimmer Biomet in the third quarter valued at about $31,000. 88.89% of the stock is owned by institutional investors.

About Zimmer Biomet

Zimmer Biomet NYSE: ZBH is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company's product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.